TTR and amyloidosis: Transthyretin amyloidosis is described as having a heterogeneous natural history, and therefore a poor prognosis, with a mean survival from diagnosis of 3.6 years for wild-type amyloidosis and 2.5 years for transthyretin amyloidosis of the Vall 122lle variant.